文献速递神经肿瘤

HMGA1作为胶质瘤预后生物标志物:巴基斯坦队列中的表达模式、生存相关性与临床启示

HMGA1 as a prognostic biomarker for gliomas: expression patterns, survival correlations, and clinical insights from a Pakistani cohort.
PubMed 文献 · J Neurooncol · 2025-04-28

该研究在巴基斯坦Aga Khan大学医院对75例胶质瘤样本和10例正常癌旁组织行实时定量PCR检测HMGA1表达,发现HMGA1在胶质瘤中显著上调并随肿瘤级别升高,高表达与Ki-67水平相关且与更差生存相关,患者死亡风险升高3.5倍(95%CI:1.5-7.9,p=0.003),ROC曲线下面积为0.752,提示其潜在预后价值,但需进一步验证。

要点

  • HMGA1在胶质瘤中较正常癌旁组织显著上调(p<0.001),且随肿瘤级别升高(p=0.015)。
  • 高HMGA1表达与Ki-67水平相关,并与更差生存相关(p=0.0014)。
  • HMGA1升高患者死亡风险为3.5倍(95%CI:1.5-7.9,p=0.003),AUC为0.752。

核心结论

  • HMGA1过表达与胶质瘤不良预后相关,提示其作为预后标志物的潜力,但需进一步验证以确认其临床效用。

研究设计与样本

  • 研究对来自巴基斯坦Aga Khan大学医院的75例胶质瘤样本及10例正常癌旁组织(NAT)行实时定量PCR(qPCR)检测HMGA1表达。
  • 采用Kaplan-Meier(KM)绘图评估HMGA1表达与胶质瘤患者预后的相关性,统计分析使用R平台并通过中国胶质瘤基因组图谱(CGGA)在线数据库在线工具进一步验证。

主要发现

  • HMGA1在胶质瘤中的表达较正常癌旁组织显著上调(p<0.001),并随肿瘤级别升高而增加(p=0.015)。
  • 高HMGA1表达与Ki-67水平相关,并与更差生存相关(p=0.0014)。
  • HMGA1升高患者的死亡风险为3.5倍(95%CI:1.5-7.9,p=0.003)。
  • ROC分析得出AUC为0.752,提示其潜在预后价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步验证以确认其临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-Mobility Group A1 (HMGA1) is a chromatin-associated protein involved in regulating key cellular processes, including DNA transcription, replication, recombination, and repair. It is highly expressed during embryogenesis and reactivated in various cancers, where it contributes to tumor progression and metastasis. We investigated the prognostic significance of HMGA1 gene expression in gliomas by comparing its expression in normal brain tissue and different glioma grades. METHODS: Real-time quantitative PCR (qPCR) was performed on 75 glioma samples obtained from Aga Khan University Hospital (Pakistan), along with 10 Normal Adjacent Tissue (NAT) samples. The correlation between HMGA1 expression and prognosis was evaluated using Kaplan-Meier (KM) plotter in glioma patients. Statistical analyses were conducted using the R platform and further validated through the online database Chinese Glioma Genome Atlas (CGGA) using online tools. RESULTS: HMGA1 expression was significantly upregulated in gliomas compared to NAT (p < 0.001) and increased with tumor grade (p = 0.015). High HMGA1 expression correlated with Ki-67 levels and was associated with worse survival (p = 0.0014). Patients with elevated HMGA1 had a 3.5-fold higher mortality risk (95% CI: 1.5-7.9, p = 0.003). ROC analysis yielded an AUC of 0.752, indicating its potential prognostic value. CONCLUSION: HMGA1 overexpression is associated with poor prognosis in gliomas, suggesting its potential as a prognostic marker. However, further validation is needed to confirm its clinical utility.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Din SU, Sufiyan S, Shah AA, et al. HMGA1 as a prognostic biomarker for gliomas: expression patterns, survival correlations, and clinical insights from a Pakistani cohort. J Neurooncol. 2025. PMID: 40293672. doi:10.1007/s11060-025-05031-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。